These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14751504)

  • 1. Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?
    Riesterer O; Tenzer A; Zingg D; Hofstetter B; Vuong V; Pruschy M; Bodis S
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):361-8. PubMed ID: 14751504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential activation of the phosphatidylinositol 3'-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells.
    Zingg D; Riesterer O; Fabbro D; Glanzmann C; Bodis S; Pruschy M
    Cancer Res; 2004 Aug; 64(15):5398-406. PubMed ID: 15289348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.
    Tenzer A; Zingg D; Rocha S; Hemmings B; Fabbro D; Glanzmann C; Schubiger PA; Bodis S; Pruschy M
    Cancer Res; 2001 Nov; 61(22):8203-10. PubMed ID: 11719451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
    She QB; Solit D; Basso A; Moasser MM
    Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PI3K-AKT pathway for cancer therapy.
    Lu Y; Wang H; Mills GB
    Rev Clin Exp Hematol; 2003 Jun; 7(2):205-28. PubMed ID: 14763163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
    Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
    Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity.
    Bagli E; Stefaniotou M; Morbidelli L; Ziche M; Psillas K; Murphy C; Fotsis T
    Cancer Res; 2004 Nov; 64(21):7936-46. PubMed ID: 15520200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells.
    Isebaert SF; Swinnen JV; McBride WH; Haustermans KM
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):239-47. PubMed ID: 21816290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.
    Gupta AK; Cerniglia GJ; Mick R; Ahmed MS; Bakanauskas VJ; Muschel RJ; McKenna WG
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):846-53. PubMed ID: 12788194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
    Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells.
    Riesterer O; Zingg D; Hummerjohann J; Bodis S; Pruschy M
    Oncogene; 2004 Jun; 23(26):4624-35. PubMed ID: 15064712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
    Liu Y; Cui B; Qiao Y; Zhang Y; Tian Y; Jiang J; Ma D; Kong B
    Int J Gynecol Cancer; 2011 Jan; 21(1):100-5. PubMed ID: 21330835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
    Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
    Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells.
    Liu H; Radisky DC; Wang F; Bissell MJ
    J Cell Biol; 2004 Feb; 164(4):603-12. PubMed ID: 14769856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.
    Kim DW; Huamani J; Fu A; Hallahan DE
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):38-46. PubMed ID: 16377414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
    Hess-Stumpp H; Haberey M; Thierauch KH
    Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HGF protects corneal epithelial cells from apoptosis by the PI-3K/Akt-1/Bad- but not the ERK1/2-mediated signaling pathway.
    Kakazu A; Chandrasekher G; Bazan HE
    Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3485-92. PubMed ID: 15452053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.